Background: Hypertension is a global health epidemic, and blood uric acid levels are a major risk factor for the development of cardiovascular and renal problems. Serum uric acid levels may be reduced as a result of treatment, which may reduce cardiovascular risk factors. Losartan has a pleiotropic uricosuric effect that lowers the risk of future cardiovascular problems.
Aims and Objectives: To study and evaluate how losartan affected serum uric acid levels in people with essential hypertension.
Materials and Methods: A source of 120 newly diagnosed participants with stage 1 and stage 2 essential hypertension aged between 31 and 65 years, both genders, with elevated serum uric acid levels, were recruited. All participants were medicated with Tablet Losartan 50 mg once daily during the morning session for 1 month. The changes in the serum uric acid levels and blood pressure at baseline, 1 month, 3 months, and 6 months were measured and analyzed.
Results: Stage-2 hypertension (53.3%) was common, followed by stage-3 (37.5%) and stage-1 hypertension (9.17%). The mean levels and mean reduction of systolic blood pressure, diastolic blood pressure, and serum uric acid levels were statistically significant (P < 0.05). Adverse drug reactions such as headache were observed in 2.5% of cases, dizziness in 1.67%, and mild hypotension in 0.83% of cases.
Conclusion: Losartan therapy for 6 months can effectively decrease the serum uric acid and blood pressure in patients with essential hypertension.
Key words: Essential Hypertension; Losartan; Blood Pressure; Serum Uric Acid
|
